BioGene Therapeutics
Biotechnology company with a recent SEC Form D offering.
Biotechnology company headquartered in AUSTIN, TEXAS. Filed SEC Form D on 20260723 for a $4.5M Regulation D offering.
Biotech
📍 AUSTIN, TEXAS
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is BioGene Therapeutics going public?
No. BioGene Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is BioGene Therapeutics' valuation in 2026?
No confirmed valuation is on record for BioGene Therapeutics. The roster shows funding and investors where they are public; it does not estimate a mark.
Has BioGene Therapeutics filed an S-1?
No public S-1 is on file for BioGene Therapeutics.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Growth
Filed SEC Form D on 20260723 for $4.5M Regulation D offering
Last Round
Form D filing — $4.55M (20260723)
Fundraising Status
Form D filing · $4.55M
privateTotal raised $4.55M
Latest Funding Round
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Form D filing | $4.55M | 20260723 | — | — |
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for BioGene Therapeutics — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-11. Re-checked weekly.
Talent Signal
No public careers page or job board could be found for BioGene Therapeutics as of 2026-08-17. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
BiotechForm DRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.